41.64
Atricure Inc stock is traded at $41.64, with a volume of 529.53K.
It is up +0.60% in the last 24 hours and up +21.47% over the past month.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
See More
Previous Close:
$41.39
Open:
$41.01
24h Volume:
529.53K
Relative Volume:
0.58
Market Cap:
$2.11B
Revenue:
$534.53M
Net Income/Loss:
$-11.45M
P/E Ratio:
-172.71
EPS:
-0.2411
Net Cash Flow:
$48.28M
1W Performance:
+7.54%
1M Performance:
+21.47%
6M Performance:
+9.98%
1Y Performance:
+17.93%
Atricure Inc Stock (ATRC) Company Profile
Name
Atricure Inc
Sector
Industry
Phone
513-755-4100
Address
7555 INNOVATION WAY, MASON, OH
Compare ATRC vs ISRG, BDX, ALC, RMD, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ATRC
Atricure Inc
|
41.64 | 1.89B | 534.53M | -11.45M | 48.28M | -0.2411 |
|
ISRG
Intuitive Surgical Inc
|
393.38 | 127.84B | 11.03B | 3.16B | 3.22B | 8.7251 |
|
BDX
Becton Dickinson Co
|
179.63 | 43.79B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
ALC
Alcon Inc
|
73.63 | 32.81B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
RMD
Resmed Inc
|
220.05 | 29.46B | 5.54B | 1.52B | 1.74B | 10.37 |
|
MDLN
Medline Inc
|
33.81 | 33.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-26 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-11-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-24 | Resumed | JP Morgan | Overweight |
| Apr-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-29-23 | Initiated | UBS | Buy |
| Aug-05-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-18-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Reiterated | Needham | Buy |
| Apr-07-20 | Initiated | Oppenheimer | Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jan-24-20 | Reiterated | Needham | Buy |
| Aug-13-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Apr-12-19 | Initiated | JP Morgan | Overweight |
| Oct-04-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Stifel | Buy |
| Jun-18-18 | Reiterated | Needham | Buy |
| Apr-27-18 | Reiterated | Needham | Buy |
| Jan-16-18 | Reiterated | Needham | Buy |
| Nov-02-17 | Reiterated | Needham | Buy |
| Jul-28-17 | Reiterated | Needham | Buy |
| May-30-17 | Resumed | Piper Jaffray | Overweight |
| Jun-30-16 | Resumed | JMP Securities | Mkt Outperform |
| Oct-28-15 | Reiterated | Needham | Buy |
| Oct-06-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-06-15 | Reiterated | Needham | Buy |
View All
Atricure Inc Stock (ATRC) Latest News
Inspire Medical Systems appoints Michael H. Carrel to its board - Medical Buyer
AtriCure, Inc. (ATRC) Beat Earnings Estimates. Here’s What Could Drive ATRC Stock Next - Yahoo Finance
AtriCure, Inc. (ATRC) Q2 2026 10-Q Report: Financial Performance, Earnings, and Stockholder Updates - Minichart
AtriCure CEO Carrel joins Inspire Medical board of directors - MassDevice
AtriCure, Inc. 2026: Revenue $153.6M, EPS $0.18— 10-Q Summary - TradingView
[10-Q] AtriCure, Inc. Quarterly Earnings Report - Stock Titan
Inspire Medical Systems adds AtriCure CEO to board - Investing.com
Inspire Medical Systems adds AtriCure CEO to board By Investing.com - Investing.com South Africa
AtriCure’s Profitability Inflection and 2026 Guidance Could Be A Game Changer For AtriCure (ATRC) - simplywall.st
Inspire's New Director Comes From AtriCure, Which Helped Over 1M Patients - Stock Titan
AtriCure Inc (ATRC) Institutional Confidence - TradingKey
AtriCure Inc (ATRC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ATRC|AtriCure Inc|Price:35.040|Chg%:+2.040 - TradingKey
AtriCure Inc (ATRC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AtriCure Inc (ATRC) Balance Sheet - TradingKey
AtriCure Inc (ATRC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AtriCure Inc (ATRC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Atricure (ATRC) - The Globe and Mail
Atricure (ATRC) Receives a Buy from Stifel Nicolaus - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Prime Medicine, Inc. (PRME) and Community Health (CYH) - The Globe and Mail
BTIG Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $45 - Moomoo
AtriCure Reports Second Quarter 2026 Financial Results - BioSpace
AtriCure revenue up 12.8% to USD 153.6M in Q2 2026 - Medical Buyer
AtriCure Inc (ATRC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AtriCure Inc (ATRC) Q2 2026 Earnings Call Highlights: Strong Rev - GuruFocus
AtriCure Inc (ATRC) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Profitability ... - Yahoo Finance
AtriCure 2Q Net $8.96M >ATRC - Moomoo
AtriCure (ATRC) Reports Strong Q2 2026 Results with Revenue Grow - GuruFocus
AtriCure Releases Q2 2026 Financial Results - AlphaStreet
AtriCure Q2 Swings to Adjusted Earnings, Revenue Rises - Moomoo
Transcript : AtriCure, Inc., Q2 2026 Earnings Call, Jul 23, 2026 - marketscreener.com
AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
AtriCure Q2 Earnings Call Highlights - TradingView
Is AtriCure Inc (ATRC) Undervalued After Q2 Earnings Beat? EPS $0.18 on Revenue of $153.6M -- GF Score 78/100 - GuruFocus
Earnings call transcript: AtriCure tops Q2 2026 estimates, shares fall after hours - Investing.com
AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
AtriCure surges 3% on earnings beat and raised guidance - Investing.com India
AtriCure surges 3% on earnings beat and raised guidance By Investing.com - Investing.com South Africa
AtriCure (NASDAQ:ATRC) Profitability Surge Drives After-Hours Rally Despite Inline Revenue - ChartMill
ATRICURE ($ATRC) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative
Q2 2026 AtriCure Inc Earnings Call Transcript - GuruFocus
AtriCure set to report earnings as competitive threat looms - Investing.com UK
(ATRC) AtriCure Expects 2026 Adjusted EPS Range $0.24-$0.32, vs. FactSet Est of $0.12 - marketscreener.com
(ATRC) AtriCure Expects 2026 Revenue Range $602M-$610M, vs. FactSet Est of $604.6M - marketscreener.com
GUIDANCE: (ATRC) AtriCure Expects 2026 Adjusted EPS Range $0.24-$0.32, Vs. FactSet Est of $0.12 - Moomoo
AtriCure: Q2 Earnings Snapshot - The Daily Independent
Earnings Flash (ATRC) AtriCure, Inc. Reports Q2 Revenue $153.6M, vs. FactSet Est of $151.8M - marketscreener.com
Earnings Flash (ATRC) AtriCure, Inc. Posts Q2 Adjusted EPS $0.18 per Share, vs. FactSet Est of $0.00 - marketscreener.com
AtriCure reports Q2 2026 revenue $153.6M, net income $9.0M and adjusted EBITDA $27.3M - TradingView
BRIEF-AtriCure Q2 Adjusted EPS USD 0.18 Vs. IBES Estimate USD 0 - TradingView
Atricure Inc Stock (ATRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atricure Inc Stock (ATRC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Yuen Maggie | Director |
Aug 05 '26 |
Sale |
38.42 |
3,500 |
134,470 |
14,015 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):